Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

BACKGROUND: Active immunization with the BNT162b2 vaccine (Pfizer–BioNTech) has been a critical mitigation tool against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease 2019 (Covid-19) pandemic. In light of reports of waning protection occurring 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Edson D., Kitchin, Nicholas, Xu, Xia, Dychter, Samuel S., Lockhart, Stephen, Gurtman, Alejandra, Perez, John L., Zerbini, Cristiano, Dever, Michael E., Jennings, Timothy W., Brandon, Donald M., Cannon, Kevin D., Koren, Michael J., Denham, Douglas S., Berhe, Mezgebe, Fitz-Patrick, David, Hammitt, Laura L., Klein, Nicola P., Nell, Haylene, Keep, Georgina, Wang, Xingbin, Koury, Kenneth, Swanson, Kena A., Cooper, David, Lu, Claire, Türeci, Özlem, Lagkadinou, Eleni, Tresnan, Dina B., Dormitzer, Philip R., Şahin, Uğur, Gruber, William C., Jansen, Kathrin U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006787/
https://www.ncbi.nlm.nih.gov/pubmed/35320659
http://dx.doi.org/10.1056/NEJMoa2200674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006787/
https://www.ncbi.nlm.nih.gov/pubmed/35320659
http://dx.doi.org/10.1056/NEJMoa2200674

Ejemplares similares